CD34 Transplant References
Mylotarg Reference Documents
- Mylotarg FDA Label
- 2017 Mylotarg ODAC FDA Briefing Document
- Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
Reference Patient Populations
- Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Jentzsch et. al.
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission? Araki, et. al.
VADC45 Prior Publications
- Efficient Engraftment of Genome Edited/Modified CD34+ HSPCs in CD45 Antibody-Drug Conjugate (ADC) Conditioned Non-Human Primates
- The Impact of CD45-Antibody-Drug Conjugate Conditioning on Clonal Patterning Post HSPC Tranplantation in Rhesus Macagues
- Deploying a CD45-Antibody Drug Conjugate for Allogeneic Hematopoietic Stem Cell Transplant in Non-Human Primates
VCAR33 Prior Publications
- ASH 2023: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33ALLO) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation (Trial in Progress)
- CD33 CAR T-cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I Multicenter Trial
VOR Prior Clinical Data Release
VOR Prior Pre-Clinical Data
- ASH 2023: Multimodal atlas of paired diagnosis and relapse AML samples enables novel therapeutic targeting of surface antigens
- ASH 2023: CD33-Deleted Hematopoietic Cells (Trem-cel) Are Protected From CD33xCD3 Bispecific Antibody Treatment And Produce Significantly Reduced Levels Of Inflammatory Cytokines In Preclinical Studies